Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$130,310 Mln
P/E Ratio
275.08
P/B Ratio
6.74
Industry P/E
--
Debt to Equity
0.16
ROE
0.02 %
ROCE
1.37 %
Div. Yield
3.02 %
Book Value
15.35
EPS
0.38
CFO
$115,888.00 Mln
EBITDA
$121,317.00 Mln
Net Profit
$75,750.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
| 12.95 | -1.45 | 13.60 | 56.28 | 17.94 | 5.13 | 0.36 |
|
BSE Sensex*
| 1.81 | 3.59 | 5.05 | 9.00 | 11.22 | 21.06 | 11.15 |
|
S&P 100
| -14.59 | -9.30 | -15.10 | 5.75 | 7.01 | 13.83 | 10.45 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
| 13.90 | -5.64 | 18.23 | 29.95 | -6.70 | 7.88 | -9.87 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 170.16 | 306,015.86 | 72.38 | 62.52 | |
| 818.02 | 754,274.86 | 71.91 | 84.41 | |
| 156.92 | 379,479.10 | 17.52 | 20.06 | |
| 77.85 | 196,278.42 | 11.57 | 40.81 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey,... Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404 Read more
Chairman & CEO
Mr. Daniel P. O'Day
Chairman & CEO
Mr. Daniel P. O'Day
Headquarters
Foster City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Gilead Sciences Inc (GILD) stood at $ 58,995 Mln as on 31-Dec-24
The share price of Gilead Sciences Inc (GILD) is $104.33 (NASDAQ) as of 21-Apr-2025 16:21 EDT. Gilead Sciences Inc (GILD) has given a return of 17.94% in the last 3 years.
Gilead Sciences Inc (GILD) has a market capitalisation of $ 130,310 Mln as on 21-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/E ratio of Gilead Sciences Inc (GILD) is 275.08 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Gilead Sciences Inc (GILD) and enter the required number of quantities and click on buy to purchase the shares of Gilead Sciences Inc (GILD).
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Address: 333 Lakeside Drive, Foster City, CA, United States, 94404
The CEO & director of Mr. Daniel P. O'Day. is Gilead Sciences Inc (GILD), and CFO & Sr. VP is Mr. Daniel P. O'Day.
There is no promoter pledging in Gilead Sciences Inc (GILD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
65,993
|
|
|
37,090
|
|
|
30,370
|
|
|
19,240
|
| Gilead Sciences Inc. (GILD) | Ratios |
|---|---|
|
Return on equity(%)
|
2.28
|
|
Operating margin(%)
|
5.8
|
|
Net Margin(%)
|
1.67
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Gilead Sciences Inc (GILD) was $480 Mln.
$-0.21
(
